Large clinical trial finds pirfenidone may help lung function in IP...( ATS 2009 SAN DIEGOA large well-contr...),Health
ATS 2009, SAN DIEGOA large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF.
In a Phase III clinical study program called "CAPACITY," investigators discovered that the oral anti-fibrotic and anti-inflammatory agent, pirfenidone, could slow the deterioration of lung capacity in patients suffering from IPF.
The researchers presented their findings on Sunday, May 17, at the American Thoracic Society's 105th International Conference in San Diego.
The CAPACITY trial consisted of two multi-national, randomized, double-blind, placebo-controlled Phase III trials (CAPACITY 1 and CAPACITY 2) designed to evaluate the safety and efficacy of pirfenidone in IPF patients with mild to moderate impairment in lung function. The primary endpoint of change in percent predicted forced vital capacity (FVC) at week 72 was met with statistical significance in CAPACITY 2 (p=0.001), along with the secondary endpoints of categorical change in FVC and progression-free survival (PFS), defined as time to either death, a 10-percent decrease in FVC or a 15-percent decrease in DLCO (diffusing capacity of the lung for carbon monoxide). The primary endpoint was not met in CAPACITY 1 (p=0.501), but evidence of a pirfenidone treatment effect on the primary endpoint was observed at several periods in that trial. Importantly, greater than 80 percent of patients in the trials completed treatment and greater than 90 percent completed the study.
An exploratory analysis of pooled data from both trials revealed that treatment with pirfenidone resulted in a 30-percent relative reduction in the percentage of patients who experienced an absolute decline in percent predicted FVC of at least 10 percent. This magnitude of decline is considered clinically meaningful, as a 10-percent decline in percent predicted FVC has been shown in multiple stud
'/>"/>
| Contact: Keely Savoie ksavoie@thoracic.org 212-315-8620 American Thoracic Society Source:Eurekalert |
Related medicine news :
1. MTF, Largest Tissue Bank, Provides Skin for Victims of Santa Barbara Wildfires
2. New Clinical Recommendations for Treating Americas Largest Healthcare Epidemic
3. NxStage Ranked Fourth Largest Revenue Gaining Company in Massachusetts for 2008
4. TeamStaff Rx Signs Staffing Agreement With One of the Nations Largest Healthcare Services Networks
5. Large Employers Strongly Oppose New Taxes On 161 Million American Workers Health Benefits
6. Prevalence of Interstitial Cystitis in U.S. Much Larger Than Previously Believed
7. Early Alzheimers diagnosis offers large social, fiscal benefits
8. Massive decline in rates of coronary death in Iceland are largely attributed to risk factor reductions in the population
9. Large Study of Lacrisert(R) Dry Eye Insert:
10. Women live longer, not better, largely because of obesity and arthritis
11. Youth to Fight Obesity With Worlds Largest Exercise Class
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |